Encouragingly, a clinical trial has reported that the combination of anti‐PD‐1 and anti‐CSF‐1R therapies may provide a durable clinical benefit for malignant glioma patients (ClinicalTrials.gov identifier: NCT02526017). The gene discussed is CSF1R; the disease is malignant glioma.